Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of HELIX BIOPHARMA CORP
No Price
Closing Price XTSE 29.04.2026:
1,96 CAD
29.04.2026 14:58
Current Prices from HELIX BIOPHARMA CORP
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
TSX
HBP.TO
CAD
29.04.2026 14:58
1,96 CAD
-0,06 CAD
-2,97 %
UTC
HBPCF
USD
28.04.2026 20:00
1,73 USD
0,00 USD
Share Float & Liquidity
Free Float65,91 %
Shares Float50,34 M
Shares Outstanding76,38 M
Company Profile for HELIX BIOPHARMA CORP Share
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
